Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol

Archives of Internal Medicine

Volumn 162, Issue 2, 2002, Pages 177-182

  Nyman, John A ^a   Martinson, Melissa S ^a   Nelson, David ^b   Nugent, Sean ^b   Collins, Dorothea ^c   Wittes, Janet ^d   Fye, Carol L ^e   Wilt, Timothy J ^b   Robins, Sander J ^f   Rubins, Hanna Bloomfield ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d University of Iowa   (United States)

^e University of New Mexico   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIMULATION; STROKE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037185430     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.2.177     Document Type: Article

References (18)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival study (4s)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
5. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol
6. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
7. Stability of time-tradeoff utilities in survivors of myocardial infarction
8. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction
9. Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy
10. Screening for hypertension
11. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
12. Some reflections on cost-effectiveness analysis
13. Distribution of lipids in 8500 men with coronary artery disease
14. The VA health care system: An unrecognized national safety net
15. Health-related quality of life in patients served by the Department of Veterans Affairs
16. Cost effectiveness of assessment and management of risk factors